

Minneapolis Heart Institute Foundation® Cardiovascular Grand Rounds

Title: Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide 1 Receptor Agonists on Cardiovascular and Limb Events, Primarily in Patients with Peripheral Artery Disease

Speaker: Nedaa Skeik, MD, FACC, FACP, FSVM
Section Head, Vascular Medicine
Medical Director, Anticoagulation Clinic
Medical Director, Vein Center
Medical Director, Vascular Lab
Allina Health Minneapolis Heart Institute

Date: December 4, 2023

Time: 7:00 - 8:00 AM

Location: Minneapolis Heart Institute Building, Suite 100, MHIF Learning Center
Webinar - visit www.mplsheart.org/grandrounds for login information

OBJECTIVES

At the completion of this activity, the participants should better be able to:

1. List the effects of SGLTi and GLP1R-A in patients with CV risk.
2. List the effects of SGLTi and GLP1R-A in patients with PAD.
3. Discuss current guidelines and evidence-based recommendations.

DISCLOSURE POLICY & STATEMENTS

Allina Health Learning & Development, Office of Accreditation intends to provide balance, independence, objectivity and scientific rigor in all of its educational activities. The ACCME defines an **ineligible company** as “any entity” whose primary business is producing, marketing, re-selling, or distributing health care products/services used by or on patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests - unless the provider of clinical service is owned, or controlled by, an ACCME-defined ineligible company. All speakers and planning committee members participating in the CME activity are required to disclose to the audience any financial relationships with ineligible companies that have existed WITHIN THE LAST 24 MONTHS, even if it has now ended.

Moderator(s)/Speaker(s) – Dr. Nedaa Skeik has disclosed the following financial relationships that have existed WITHIN THE LAST 24 MONTHS with the following ineligible company(s) even if it has now ended as it relates to presenting the content in this CME activity: AstraZeneca (Existing), Janssen (Existing), Pfizer (Prior).

NON-ENDORSEMENT OF COMMERCIAL PRODUCTS AND/OR SERVICES

We would like to thank the following company for exhibiting at our activity.

Janssen Pulmonary Hypertension

United Therapeutics Corporation

Accreditation of this educational activity by Allina Health does not imply endorsement by Allina Learning & Development of any commercial products displayed in conjunction with an activity. A reminder for Allina employees and staff, the Allina Policy on Ethical Relationship with Industry prohibits taking back to your place of work any items received at this activity with branded and or product information from our exhibitors.